You are here
The FDA has approved a stem cell therapy that will work to repair damage caused by heart attacks, according to a release from the California Institute for Regenerative Medicine. The approval will be the first-in-human use for the therapy in clinical trials.
California Gov. Arnold Schwarzenegger inked SB 1237the California Dose Reporting Lawin September 2010. Designed as a quality control initiative for CT scans, the bill plunges imaging stakeholders and hospitals into uncharted waters.
Today, sadly, marks my last day with Cardiovascular Business. For almost three years, I have had the pleasure and honor of working with the crew here at CVB and all of you. It is a bittersweet goodbye for me, but I am moving on to start a new adventure in Beantown.
In 2008, the state of Massachusetts passed a controversial bill requiring payments of more than $50 to physicians from industry to be reported. But on July 3, Massachusetts Gov. Deval Patrick repealed part of the Massachusetts Pharmaceutical and Medical Device Gift Ban and Disclosure Law, which will now allow pharmaceutical or device companies to pay for modest meals and refreshments.
In a June 25 vote, the National Quality Forum (NQF) board of directors upheld a previous decision to endorse an all-cause hospitalwide readmission measure that was developed by both the Centers for Medicare & Medicaid Services (CMS) and Yale University.
Results of a clinical trial showed that the 32 mg dose of the anti-nausea drug ondansetron (Zofran) could negatively affect a patients heart. FDA and GlaxoSmithKline have placed warnings on the drug, saying that intravenous doses of the drug should not exceed 16 mg.
Health is better than wealth, they say, but can you get there without money? Hospitals today face tough times as they attempt to balance top-notch patient care and dwindling resources. But while many say innovation will be the missing piece to the puzzle, will it be affordable?
FDA has weighed in on the latest weight-loss drug lorcaserin hydrochloride (Belviq), approving the Arena Pharmaceutical drug for use in adults with a body mass index (BMI) of 30 or greater and those with a BMI more than 27 and hypertension, type 2 diabetes or dyslipidemia.
As the healthcare community strives to become more transparent as a means to improve care, some have turned to cardiac surgery quality assessments or physician report cards. However, others turn their noses up to these types of public report cards, saying that the information may not always be 100 percent accurate.
Everyone looks for some sort of approval, but where we find it is sometimes a different story. In the case of the transcatheter aortic heart valve, Edwards Lifesciences may be one step closer to finding it after FDAs Circulatory Systems Device Panel voted in favor of expanding device indications to include aortic stenosis patients at a high risk for surgery. While the journey for transcatheter aortic valve replacement (TAVR) has been long, as writer Mark Twain wrote, We can secure other people's approval, if we do right and try hard.